A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

PHASE2RecruitingINTERVENTIONAL

Enrollment

234

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

January 12, 2027

Study Completion Date

July 16, 2027

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

Adjuvanted RSVPreF3 vaccine

1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).

Trial Locations (2)

RECRUITING

GSK Investigational Site, St Louis

RECRUITING

GSK Investigational Site, Kumamoto